All In Biotech

Drug Trial Radar · NCT06387420

A Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid Leukemia

A Phase 1b/2 Study of AK117 (Anti-CD47 Antibody) in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid Leukemia

Last checked: Nov 19, 2026Latest source record: Apr 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 180 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

180

Planned (sponsor's estimate)

Start

Apr 29, 2024

Primary completion

Apr 2026

Study completion Apr 2027

Sponsor

Lead sponsor
AkesoIndustry
Sponsor type
Industry
First posted
Apr 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 1b/2 study. All patients are diagnosed with Acute Myeloid Leukemia (AML), Eastern Cooperative Oncology Group (ECOG) performance status 0-3. The purpose of this study is to evaluate the safety and efficacy of AK117 + azacitidine + venetoclax in subjects with AML.

Conditions

  • ACUTE MYELOID LEUKEMIA; AML

Interventions

  • AK117Drug

    Subjects receive AK117 intravenously.

  • AzacitidineDrug

    Subjects receive azacitidine subcutaneously.

  • VenetoclaxDrug

    Subjects receive venetoclax orally.

  • PlaceboOther

    Subjects receive placebo intravenously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1b: Number of participants with dose limiting toxicity (DLT)Time frame: At the end of Cycle 1 (each cycle is 28 days)
  2. Phase 1b/2: Number of participants with adverse events (AEs)Time frame: Up to approximately 2 years.
  3. Phase 1b/2: Composite complete remission rate (CCR)Time frame: Time Frame: Up to approximately 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College

    Tianjin, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.